Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, and Division of Infectious Disease, Santa Clara Valley Medical Center, San Jose, California
The efficacy of vancomycin for the treatment of patients with infections due to Staphylococcus aureus is impaired by its poor tissue penetration and by its relatively weak antibacterial activity—an activity that is declining as S. aureus evolves. Neither dose escalation nor use of vancomycin in combination with other antibiotics that have antistaphylcoccal activity has been demonstrated to safely enhance its therapeutic efficacy. Although no clinical trials suggest superiority of vancomycin over any comparator, some have provided evidence of its inferiority. Strong consideration should be given to the use of alternative agents in the treatment of serious S. aureus infections.
Cited by
R. K. C. Fong, J. Low, T. H. Koh, A. Kurup. (2009) Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
European Journal of Clinical Microbiology & Infectious Diseases Online publication date: 22-May-2009.
CrossRef E. Cock, W. A. Krueger, S. Sorensen, T. Baker, J. Hardewig, S. Duttagupta, E. Müller, A. Piecyk, E. Reisinger, A. Resch. (2009) Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany.
Infection 37:2, 123-132
Online publication date: 1-May-2009.
CrossRef Aryun Kim, George Sakoulas, Joseph L. Kuti, David P. Nicolau. (2009) Prevalence of Methicillin-Resistant Staphylococcus aureus Strains With Vancomycin Minimum Inhibitory Concentration 2 μg/mL in New York City Area Hospitals and Implications on Pharmacodynamic Target Attainment.
Infectious Diseases in Clinical Practice 17:2, 95-98
Online publication date: 1-Apr-2009.
CrossRef Peter K Linden. (2009) Vancomycin resistance: are there better glycopeptides coming?.
Expert Review of Anti-infective Therapy 6:6, 917-928
Online publication date: 1-Jan-2009.
CrossRef Natasha VDV Ratnaraja, Peter M Hawkey. (2008) Current challenges in treating MRSA: what are the options?.
Expert Review of Anti-infective Therapy 6:5, 601-618
Online publication date: 1-Nov-2008.
CrossRef Blanca E. Gonzalez, Sheldon L. Kaplan. (2008) Severe Staphylococcal Infections in Children.
Pediatric Annals 37:10, 686-693
Online publication date: 1-Nov-2008.
CrossRef Marin H. Kollef, Lena M. Napolitano, Joseph S. Solomkin, Richard G. Wunderink, In‐Gyu Bae, Vance G. Fowler, Robert A. Balk, Dennis L. Stevens, James J. Rahal, Andrew F. Shorr, Peter K. Linden, and Scott T. Micek. (2008) Health Care–Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit.
Clinical Infectious Diseases 47:s2, S55-S99
Online publication date: 1-Oct-2008.
Esteban C Nannini, Martin E Stryjewski. (2008) A new lipoglycopeptide: telavancin.
Expert Opinion on Pharmacotherapy 9:12, 2197-2207
Online publication date: 1-Sep-2008.
CrossRef I. Kappstein, K. Mühlen, D. Meschzan, V. Vatou, S. Bieg-Habermann. (2008) Prävention von MRSA-Übertragungen: Standardhygiene statt Isolierung.
Der Chirurg Online publication date: 20-Jul-2008.
CrossRef P. R. Ingram, D. C. Lye, P. A. Tambyah, W. P. Goh, V. H. Tam, D. A. Fisher. (2008) Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
Journal of Antimicrobial Chemotherapy 62:1, 168-171
Online publication date: 1-May-2008.
CrossRef Y. Carmeli. (2008) Strategies for managing today’s infections.
Clinical Microbiology and Infection 14:s3, 22-31
Online publication date: 1-May-2008.
CrossRef P. Moreillon. (2008) New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
Clinical Microbiology and Infection 14:s3, 32-41
Online publication date: 1-May-2008.
CrossRef William J Peppard, Carolyn J Johnston, Angela M Urmanski. (2008) Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
Expert Review of Anti-infective Therapy 6:1, 83-99
Online publication date: 1-Mar-2008.
CrossRef Richard A. Proctor. (2008) Clinical Practice: Role of Folate Antagonists in the Treatment of Methicillin‐Resistant
Staphylococcus aureus Infection.
Clinical Infectious Diseases 46:4, 584-593
Online publication date: 15-Feb-2008.
Jaime Fergie, Kevin Purcell. (2008) The Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections.
The Pediatric Infectious Disease Journal 27:1, 67-68
Online publication date: 1-Feb-2008.
CrossRef Ilker Uçkay, Stephan Harbarth, Didier Pittet. (2008) Management of Gram-positive bacteraemia.
Current Opinion in Infectious Diseases 20:6, 561-567
Online publication date: 1-Jan-2008.
CrossRef Cindy A Loffler, Conan MacDougall. (2008) Update on prevalence and treatment of methicillin-resistant
Staphylococcus aureus infections.
Expert Review of Anti-infective Therapy 5:6, 961-981
Online publication date: 1-Jan-2008.
CrossRef Barry I Eisenstein. (2007) Use of daptomycin for treatment of
Staphylococcus aureus infections.
Expert Opinion on Drug Discovery 2:11, 1523-1536
Online publication date: 1-Dec-2007.
CrossRef Stan Deresinski. (2007) Principles of Antibiotic Therapy in Severe Infections: Optimizing the Therapeutic Approach by Use of Laboratory and Clinical Data.
Clinical Infectious Diseases 45:s3, S177-S183
Online publication date: 15-Sep-2007.